Leukemia

Ponatinib continues to make improvements in phase 2 CML study.

A study shows that a chemotherapy-free regimen may be better in acute promyelocytic leukemia.

When considering a stem cell transplantation, patients with cancer must be willing to take a chance.

Cancer research updates from the San Antonio Breast Cancer Symposium and American Society of Hematology.

Childhood and young adult cancer survivors need fertility preservation information, but are they getting it from their oncologists?

A kid can bring out the best in people.

Creating Hope for Childhood Cancer

Survival rates for ALL have increased to about 90 percent.

The latest in cancer prevention, diagnosis & treatment.

Minimizing and preventing late effects of stem cell transplantation.

Birth defects rare in kids of childhood cancer survivors.

In an early-phase study, PCI-32765, a BTK inhibitor, was shown to work against CLL, a type of non-Hodgkin lymphoma.

A novel drug called ponatinib that targets the BCR-ABL mutation overcomes a mutation that has been resistant to all previous approved therapies.

A drug removed from the market last year to treat acute myeloid leukemia may have a second life.

Research updates from the annual San Antonio Breast Cancer Symposium and American Society of Hematology.

The latest in cancer prevention, diagnosis and treatment.

Study shows adult survivors of childhood cancer may have sleep issues that negatively affect cognitive function.

New research has shown that high-dose methotrexate improved five-year event-free survival for ALL patients with no significant differences in toxicities.

Adolescents with AML tend to do better with stem cell transplant.

Online tool helps cancer survivors know what to look for years after treatment

Study shows experimental drug ponatinib acts against a mutation found in small percentage of chronic myeloid leukemia cases that is resistant to other forms of therapy

Treatment differs for Acute myeloid leukemia pediatric patients compared with older adults.

Chronic myeloid leukemia (CML)usually can be managed as a chronic disease by therapies, including Gleevec (imatinib) or two newer drugs, Sprycel (dasatinib) or Tasigna (nilotinib).

Updates from the annual meetings of the American Society of Hematology and the San Antonio Breast Cancer Symposium.

The latest in cancer prevention, diagnosis & treatment